Abstract:Anti-PD-1 immunotherapy brings hope for the treatment of malignant tumors, but its overall response rate is low. Therefore, how to sensitize anti-PD-1 therapy to make more patients benefit from immunotherapy is an urgent clinical demand. PKCι, a classical oncogene that affects cell proliferation and differentiation, has recently been found to be involved in the recruitment of immunosuppressive cells MDSCs and Tregs, which leads to anti-PD1 immunotherapy resistance. Our study is consistent with previously reported results that interfering with PKCι expression in tumor cells significantly enhances the anti-tumor effect of anti-PD1 therapy. Immunological mechanistic analyses demonstrated that the inhibition of PKCι expression significantly reduced the infiltration of tumor-associated macrophages (TAMs) rather than MDSCs or Tregs. Further studies revealed that PKCι enhanced the expression of macrophage chemokine CCL7 by promoting the formation of the YAP1/TEAD transcriptional complex. Interference in vitro and pharmacological inhibition of PKCι in tumor cells both significantly reduced CCL7 expression and TAMs invasion. Auranofin is a commonly used anti-inflammatory agent in clinical practice, which has been recently found that it directly induces tumor death by modulating the cellular redox system in tumor cells and remodels the tumor immunosuppressive microenvironment by specifically inhibiting PKCι expression. The results of our study showed that the anti-tumor effect of Auranofin combined with anti-PD1 therapy was superior to that of monotherapy in lung adenocarcinoma. Auranofin exerted synergistic anti-tumor effects with anti-PD1 immunotherapy by inhibiting the expression of PKCι-YAP1/TEAD-CCL7, reducing the recruitment of TAMs, and promoting the infiltration of effector CD8+ T cells. In summary, Auranofin is a potent candidate for sensitizing anti-PD-1 immunotherapy, reversing immunotherapy blunting by remodeling TIME, which provides new ideas and theoretical basis for immunotherapy of sensitizing malignant tumors. Citation Format: Zichen Zhao, Shichuan Hu, Yan Zhang. Auranofin enhances the efficacy of anti-PD1 immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4997.

Repurposing auranofin and meclofenamic acid as energy-metabolism inhibitors and anti-cancer drugs

The Architecture and Function of Monoclonal Antibody-Functionalized Mesoporous Silica Nanoparticles Loaded with Mifepristone: Repurposing Abortifacient for Cancer Metastatic Chemoprevention.

Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition

Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells.

Suppression of Metastasis by Citrus Auraptene in a Mouse Model of Colorectal Cancer

Abstract 5311: Auranofin sensitizes paclitaxel induced apoptotic cell death through oxidative mechanism in breast cancer cells

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy

Strategies for the design of analogs of auranofin endowed with anticancer potential

Repurposing drugs as pro‐oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers

Auranofin as a Novel Anticancer Drug for Anaplastic Thyroid Cancer

The rheumatoid arthritis drug auranofin exerts potent anti-lymphoma effect by stimulating TXNRD-mediated ROS generation and inhibition of energy metabolism

Design, synthesis and anticancer evaluation of polymethoxy aurones as potential cell cycle inhibitors

Targeting Metabolic Dependencies in Acute Myeloid Leukemia: A Dual Strategy using Arsenic Trioxide and Artesunate.

Experimental evaluation of the effects of anticancer modulation therapy on MAPK/PI3K/AKT/mTOR/NF-κB signaling with non-toxic drugs

Mitochondrial Functionality Is Regulated by Alkylphospholipids in Human Colon Cancer Cells

Repurposing mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 for cancer therapy

Abstract 4997: Auranofin enhances the efficacy of anti-PD1 immunotherapy

The effects and mechanisms of aloe‐emodin on reversing adriamycin‐induced resistance of MCF ‐7/ ADR cells

Cancer Pro-oxidant Therapy Through Copper Redox Cycling: Repurposing Disulfiram and Tetrathiomolybdate

Additive Cytotoxic and Colony-Formation Inhibitory Effects of Aspirin and Metformin on PI3KCA-Mutant Colorectal Cancer Cells

Repurposing antiplasmodial leads for cancer: Exploring the antiproliferative effects of N-cinnamoyl-aminoacridines